ArticleThe Journal of clinical investigation2010
Comeback kids: CD8(+) suppressor T cells are back in the game.
Article in The Journal of clinical investigation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- GPR15-guided CD8Nature · 2026Article
- Prior murine neurotropic coronavirus infection ameliorates experimental autoimmune encephalitis.Journal of autoimmunity · 2026Article
- Innate and Innate-like Effector Lymphocytes in Health and Disease.Journal of immunology (Baltimore, Md. : 1950) · 2022Review
- A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients.The Journal of experimental medicine · 2022Article
- Preface: Unconventional T Cells in Health and Disease.Critical reviews in immunology · 2021Article
- Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE.Cellular & molecular immunology · 2019Review
- Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity.The Journal of allergy and clinical immunology · 2013Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suppressing unwanted immune responses without compromising host immunity against pathogens is considered the holy grail of immunology. Lack of responsiveness to self-antigens is normally maintained by multiple mechanisms, including the suppressive activities of several T cell subsets. In this issue of the JCI, Jiang and colleagues define a CD8(+) suppressor T cell subset in humans that recapitulates a regulatory pathway previously described in mice. These investigators further show that patients with type 1 diabetes have defects in their CD8(+) suppressor T cells, thus identifying these cells as potential therapeutic targets in human disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.